GE HealthCare Technologies Inc. (GEHC)

業務介紹

通用電氣健康護理技術公司從事產品、服務和配套數字解決方案的開發、製造和營銷,用於診斷、治療和監測美國、加拿大、歐洲、中東、非洲、中國、台灣、蒙古和香港等地的患者。該公司通過四個業務部門運營:成像、超聲波、患者護理解決方案和製藥診斷。成像部門提供分子成像、計算機斷層掃描(CT)、磁共振(MR)成像、影像引導療法和X射線系統,以及婦女健康產品。超聲波部門提供通過放射學和初級保健、婦女健康、心血管和點護理以及手持超聲波解決方案進行篩查、診斷、治療和監測某些疾病的產品,以及手術可視化和指導產品。患者護理解決方案部門提供醫療設備、耗材產品、服務和數字解決方案,涉及患者監測、麻醉輸送和呼吸護理、診斷心臟病學和母嬰護理產品。製藥診斷部門供應診斷試劑,包括CT、血管造影和X射線、MR、單光子發射計算機斷層掃描、正電子發射斷層掃描和超聲波,供放射學和核醫學行業使用。該部門還提供對比劑藥物,在某些診斷掃描前給予患者,以增加成像檢查期間組織或結構的可見性;以及分子成像試劑或放射性藥物,即標有放射性同位素的分子示蹤劑,在診斷成像掃描前注射到患者體內。該公司於2022年註冊成立,總部位於伊利諾伊州芝加哥。



GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

公司網址

https://www.gehealthcare.com